Patient-reported outcome Research (Qol, fatigue, sleep, cognition, anxiety, depression)

Studies in cooperation with Prof. R. Schlenk and Prof. A. Schneeweiss (selection)

  • SarcBOP “A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Soft-tissue and Bone Sarcoma”
    In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg

  • Q-HAM “Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD”
    Phase II clinical trial in cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg

  • MyBOP „A prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients with Myeloid Neoplasms“
    In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelbeg

  • GnG "Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in older patients with newly diagnosed AML"
    The study is a randomized phase III trial with a 2x2 factorial design with measurable residual disease and event-free survival as primary endpoints, respectively. In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg

  • COGNITION-Studie
    Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials: frühe Hochrisiko-Mammakarzinome.
    In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg

  • CATCH-Studie
    Comprehensive assessment of clinical features and biomarkers to identify patients with advanced or metastatic breast cancer for marker driven trials in humans): fortgeschrittene / metastasierte Mammakarzinome.
    In cooperation with Prof. Dr. Richard Schlenk, National Center for Tumor Diseases (NCT), Heidelberg and the Medical University of Heidelberg

 

to top
powered by webEdition CMS